江苏亚虹医药科技股份有限公司2025年年度业绩预亏公告

Core Viewpoint - Jiangsu Yahon Pharmaceutical Technology Co., Ltd. expects a significant net loss for the fiscal year 2025, with projections indicating a loss between 377.67 million yuan and 453.20 million yuan, reflecting an increase in losses compared to the previous year [2][3]. Financial Performance Forecast - The company anticipates a net profit attributable to shareholders of the parent company for 2025 to be between -377.67 million yuan and -453.20 million yuan, representing a year-on-year increase in losses of 18.00% to a decrease of 1.67% [2][3]. - The expected net profit after deducting non-recurring gains and losses is projected to be between -396.29 million yuan and -475.55 million yuan, with a year-on-year increase in losses of 16.28% to a decrease of 3.10% [2][3]. - Estimated operating revenue for 2025 is projected to be between 242.48 million yuan and 290.98 million yuan, indicating a year-on-year increase of 20.30% to 44.36% [3]. - Research and development expenses are expected to be between 253.67 million yuan and 304.40 million yuan, reflecting a decrease of 2.41% to 18.67% compared to the previous year [3]. Previous Year Performance - In 2024, the company reported a total profit of -386.80 million yuan, with a net profit attributable to shareholders of the parent company at -384.06 million yuan and a net profit after deducting non-recurring gains and losses at -408.95 million yuan [5]. Business Development and R&D Progress - The company's revenue primarily comes from the sales of Pazopanib tablets and Neralitinib tablets, with steady growth in sales and volume expected for 2025 [6]. - The company has made significant progress in multiple product developments, including the APL-1702 clinical trial results being presented at an international conference and the acceleration of its market approval process [7]. - APL-2401, a first-class innovative drug, received approval for clinical trials, demonstrating compliance with international standards and benefiting from expedited review processes [8]. - The company is also developing a portable disposable blue light bladder endoscope, APLD-2304, aimed at improving bladder cancer detection rates and patient comfort [8]. - Positive preliminary results were reported for APL-1401 in treating moderate to severe active ulcerative colitis, with plans for further evaluation in larger patient groups [9].